Antisense Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its produc… Read more
Antisense Therapeutics Limited (ATHJF) - Net Assets
Latest net assets as of June 2024: $9.36 Million USD
Based on the latest financial reports, Antisense Therapeutics Limited (ATHJF) has net assets worth $9.36 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.53 Million) and total liabilities ($5.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.36 Million |
| % of Total Assets | 64.44% |
| Annual Growth Rate | -3.25% |
| 5-Year Change | 106.65% |
| 10-Year Change | 32.03% |
| Growth Volatility | 91.45 |
Antisense Therapeutics Limited - Net Assets Trend (2001–2024)
This chart illustrates how Antisense Therapeutics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Antisense Therapeutics Limited (2001–2024)
The table below shows the annual net assets of Antisense Therapeutics Limited from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $9.36 Million | -6.14% |
| 2023-06-30 | $9.98 Million | -52.81% |
| 2022-06-30 | $21.14 Million | +269.12% |
| 2021-06-30 | $5.73 Million | +26.41% |
| 2020-06-30 | $4.53 Million | +61.26% |
| 2019-06-30 | $2.81 Million | -33.44% |
| 2018-06-30 | $4.22 Million | +127.76% |
| 2017-06-30 | $1.85 Million | -59.51% |
| 2016-06-30 | $4.58 Million | -35.46% |
| 2015-06-30 | $7.09 Million | +239.82% |
| 2014-06-30 | $2.09 Million | -55.09% |
| 2013-06-30 | $4.65 Million | -11.75% |
| 2012-06-30 | $5.27 Million | +160.93% |
| 2011-06-30 | $2.02 Million | +50.15% |
| 2010-06-30 | $1.34 Million | -65.78% |
| 2009-06-30 | $3.93 Million | -38.00% |
| 2008-06-30 | $6.33 Million | +5.27% |
| 2007-06-30 | $6.02 Million | -31.57% |
| 2006-06-30 | $8.79 Million | -19.06% |
| 2005-06-30 | $10.86 Million | -36.59% |
| 2004-06-30 | $17.13 Million | +47.47% |
| 2003-06-30 | $11.62 Million | -13.83% |
| 2002-06-30 | $13.48 Million | -32.71% |
| 2001-06-30 | $20.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Antisense Therapeutics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10133650200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $109.37 Million | 1168.11% |
| Other Comprehensive Income | $1.72 Million | 18.39% |
| Total Equity | $9.36 Million | 100.00% |
Antisense Therapeutics Limited Competitors by Market Cap
The table below lists competitors of Antisense Therapeutics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bluerock Homes Trust Inc.
NYSE MKT:BHM
|
$26.77 Million |
|
RTRZY
OTCGREY:RTRZY
|
$26.78 Million |
|
Shinyoung Waco
KO:005800
|
$26.78 Million |
|
NexturnBioscience Co. Ltd
KQ:089140
|
$26.78 Million |
|
Home Loan Financial Corp
PINK:HLFN
|
$26.77 Million |
|
GameSquare Holdings Inc.
NASDAQ:GAME
|
$26.76 Million |
|
Iqstel Inc
OTCQX:IQST
|
$26.76 Million |
|
Garo AB
ST:GARO
|
$26.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Antisense Therapeutics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 9,975,665 to 9,363,087, a change of -612,578 (-6.1%).
- Net loss of 11,919,223 reduced equity.
- Share repurchases of 503,275 reduced equity.
- New share issuances of 11,611,522 increased equity.
- Other comprehensive income decreased equity by 2,279,802.
- Other factors increased equity by 2,478,200.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.92 Million | -127.3% |
| Share Repurchases | $503.27K | -5.38% |
| Share Issuances | $11.61 Million | +124.01% |
| Other Comprehensive Income | $-2.28 Million | -24.35% |
| Other Changes | $2.48 Million | +26.47% |
| Total Change | $- | -6.14% |
Book Value vs Market Value Analysis
This analysis compares Antisense Therapeutics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.54x to 3.95x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | $0.08 | $0.04 | x |
| 2008-06-30 | $0.08 | $0.04 | x |
| 2015-06-30 | $0.04 | $0.04 | x |
| 2016-06-30 | $0.03 | $0.04 | x |
| 2017-06-30 | $0.01 | $0.04 | x |
| 2018-06-30 | $0.02 | $0.04 | x |
| 2019-06-30 | $0.01 | $0.04 | x |
| 2020-06-30 | $0.01 | $0.04 | x |
| 2021-06-30 | $0.01 | $0.04 | x |
| 2022-06-30 | $0.03 | $0.04 | x |
| 2023-06-30 | $0.01 | $0.04 | x |
| 2024-06-30 | $0.01 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Antisense Therapeutics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -127.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -401.57%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.55x
- Recent ROE (-127.30%) is below the historical average (-88.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -80.37% | -634.33% | 0.09x | 1.34x | $-5.44 Million |
| 2008 | -33.73% | -33.39% | 0.65x | 1.56x | $-2.77 Million |
| 2014 | -144.39% | -246.20% | 0.46x | 1.27x | $-3.22 Million |
| 2015 | 9.97% | 18.30% | 0.50x | 1.08x | $-2.24K |
| 2016 | -54.93% | -251.44% | 0.19x | 1.16x | $-2.97 Million |
| 2017 | -148.63% | -3985.82% | 0.03x | 1.37x | $-2.94 Million |
| 2018 | -55.22% | -855.66% | 0.06x | 1.14x | $-2.75 Million |
| 2019 | -104.80% | -501.80% | 0.16x | 1.32x | $-3.23 Million |
| 2020 | -130.40% | -883.89% | 0.12x | 1.18x | $-6.36 Million |
| 2021 | -140.73% | -1395.14% | 0.08x | 1.22x | $-8.63 Million |
| 2022 | -27.49% | -326.89% | 0.08x | 1.06x | $-7.93 Million |
| 2023 | -114.08% | -720.31% | 0.12x | 1.29x | $-12.38 Million |
| 2024 | -127.30% | -401.57% | 0.20x | 1.55x | $-12.86 Million |
Industry Comparison
This section compares Antisense Therapeutics Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Antisense Therapeutics Limited (ATHJF) | $9.36 Million | -80.37% | 0.55x | $26.77 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |